- Home
- VVPR vs IMUX Comparison
VVPR vs IMUX Comparison
Compare VVPR & IMUX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VVPR
- IMUX
- Stock Information
- Founded
- VVPR 2014
- IMUX 2016
- Country
- VVPR United Kingdom
- IMUX United States
- Employees
- VVPR N/A
- IMUX N/A
- Industry
- VVPR Power Generation
- IMUX Biotechnology: Pharmaceutical Preparations
- Sector
- VVPR Utilities
- IMUX Health Care
- Exchange
- VVPR Nasdaq
- IMUX Nasdaq
- Market Cap
- VVPR 62.7M
- IMUX 67.1M
- IPO Year
- VVPR 2016
- IMUX N/A
- Fundamental
- Price
- VVPR $3.69
- IMUX $0.72
- Analyst Decision
- VVPR
- IMUX Strong Buy
- Analyst Count
- VVPR 0
- IMUX 6
- Target Price
- VVPR N/A
- IMUX $11.60
- AVG Volume (30 Days)
- VVPR 1.4M
- IMUX 2.8M
- Earning Date
- VVPR 01-01-0001
- IMUX 08-07-2025
- Dividend Yield
- VVPR N/A
- IMUX N/A
- EPS Growth
- VVPR N/A
- IMUX N/A
- EPS
- VVPR N/A
- IMUX N/A
- Revenue
- VVPR $79,000.00
- IMUX N/A
- Revenue This Year
- VVPR N/A
- IMUX N/A
- Revenue Next Year
- VVPR N/A
- IMUX N/A
- P/E Ratio
- VVPR N/A
- IMUX N/A
- Revenue Growth
- VVPR N/A
- IMUX N/A
- 52 Week Low
- VVPR $0.62
- IMUX $0.56
- 52 Week High
- VVPR $8.88
- IMUX $2.11
- Technical
- Relative Strength Index (RSI)
- VVPR 40.07
- IMUX 36.49
- Support Level
- VVPR $3.60
- IMUX $0.68
- Resistance Level
- VVPR $7.20
- IMUX $0.77
- Average True Range (ATR)
- VVPR 0.72
- IMUX 0.07
- MACD
- VVPR -0.32
- IMUX -0.00
- Stochastic Oscillator
- VVPR 6.05
- IMUX 14.09
About VVPR VivoPower International PLC
Vivopower International PLC is a solar power company. It provides energy infrastructure generation, and distribution solutions and is also engaged in the development, construction, and sale of photovoltaic(PV) solar projects. Its operating segments include Solar Development, Critical Power Services, Sustainable Energy Solutions, Electric Vehicles, and Corporate Office. The majority of the firm's revenue is generated from the Electric Vehicles segment. Geographically its key revenue derives from the Netherlands.
About IMUX Immunic Inc.
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.